TY - JOUR
T1 - Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
AU - Rosshandler, Yasmin
AU - Shen, Ann Q.
AU - Cortes, Jorge
AU - Khoury, Hanna Jean
PY - 2016/5/3
Y1 - 2016/5/3
N2 - Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
AB - Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
KW - Chronic myeloid leukemia
KW - omacetaxine mepesuccinate
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=84964460629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964460629&partnerID=8YFLogxK
U2 - 10.1586/17474086.2016.1151351
DO - 10.1586/17474086.2016.1151351
M3 - Review article
C2 - 26853281
AN - SCOPUS:84964460629
SN - 1747-4086
VL - 9
SP - 419
EP - 424
JO - Expert Review of Hematology
JF - Expert Review of Hematology
IS - 5
ER -